Iran applied for IMF money in mid-March as the Covid-19 pandemic was overwhelming its national healthcare system. Tehran hadn't asked for IMF assistance since the early 1960s and said it needed the money urgently to fight the coronavirus. The international organization, however, was not forthcoming as the US openly objected to providing any funds to Iran.

"I urge international organizations to fulfill their duties... we are a member of the IMF... There should be no discrimination in giving loans," Iranian President Hassan Rouhani said in a televised cabinet meeting on Wednesday. He added that the imposition of US sanctions against Iran amid the pandemic was "economic and medical terrorism."

Tehran is seeking $5 billion from the IMF, but Washington claims the money would be diverted and used "to help their terrorist proxy groups in the Middle East," as spokesperson for the US Department of State Morgan Ortagus told BBC Persian this week.

© Reuters / WANA (West Asia News Agency) / Ali KharaA shopping mall turned into a centre to receive Covid-19 patients in Tehran

The US is the largest IMF shareholder and has much sway over its decisions on whether to grant bailouts to nations. Washington will use its leverage to block Iran's request and is also preventing Tehran from tapping into the roughly $5 billion in reserves held in its account at the IMF, the Wall Street Journal reported.

The Trump administration has been pursuing 'maximum pressure' against Iran, threatening people doing business with it with secondary sanctions. Washington suggests Tehran should get money for fighting the pandemic by diverting some from national defense.

Iranian officials are hopeful that other IMF members will defy the US, which - despite its influence - doesn't have a veto power in the organization.

"Actually it's a policy of the IMF for evenhandedness in appraisal and approval of requests," Iranian Vice-President for Economic Affairs Mohammad Nahavandian told CNN's Christiane Amanpour.

"Iran has been a founding member of IMF, with very good record. And it is expected for this international body to do what [it] is expected to do. That request is now in due process. Many countries have expressed their support for this," he added.

The minister pointed out that "we are all in the same boat" with the threat of the pandemic, so compromising Iran's public health by denying it a bailout would undermine other nations as well.

Some global players have publicly criticized the US for maintaining its sanctions amid the coronavirus outbreak. Washington's European allies Germany, France and Britain used the sanctions-dodging barter mechanism INSTEX to deliver medical supplies to Iran for the first time in late March.

Professor Mauro Ferrari submitted his resignation to European Commission President Ursula von der Leyen on Tuesday, effective immediately. His four-year term ended abruptly just months after starting on January 1. Ferrari said he was "extremely disappointed by the European response to Covid-19."

Ferrari headed the European Research Council (ERC), a body established in 2007 with a multibillion-euro budget with the goal of supporting scientific discovery in the EU. The ERC's 'bottom-up' approach to distributing grants clashed with Ferrari's suggestion of launching a large-scale effort to fight the pandemic.

"I thought that at a time like this, the very best scientists in the world should be provided with resources and opportunities to fight the pandemic, with new drugs, new vaccines, new diagnostic tools, new behavioral dynamic approaches based on science, to replace the oft-improvised intuitions of political leaders."

The proposal was rejected by ERC's Scientific Council. Ferrari said he tried to get his ideas implemented through von der Leyen, but the very fact of him working directly with the Commission head "created an internal political thunderstorm. The proposal was passed on to different layers of European Commission administration, where I believe it disintegrated upon impact."

Ferrari is a US-Italian nanomedicine pioneer focusing on developing new cancer treatments.